Similar to HA-NPs, CB1R antagonists improve obesity-induced insulin resistance by suppressing adipose tissue inflammation via the NLRP3 inflammasome as well as reduce fat accumulation and body weight in DIO mice [107,108]. Here, CNR1 is linked to obesity disorder.